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Periprocedural Bridging in Patients with Venous Thromboembolism: A Systematic 
Review 
Clinical Significance  
 
Word count: 60 
 Periprocedural bridging is widely used in patients with previous venous thromboembolism 
who require interruption of vitamin K antagonists due to an invasive procedure 
 This systematic review found that periprocedural bridging in patients with previous venous 
thromboembolism increases the risk of bleeding without reducing the risk of periprocedural 
venous thromboembolism  
 Most patients with venous thromboembolism do not benefit from periprocedural bridging 
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Abstract 
Background 
Vitamin K antagonists (VKA) are the most widely used anticoagulants, and bridging is commonly 
administered during periprocedural VKA interruption. Given the unclear benefits and risks of 
periprocedural bridging in patients with previous venous thromboembolism, we aimed to assess 
recurrent venous thromboembolism and bleeding outcomes with and without bridging in this 
population. 
Methods  
We performed a systematic review searching the PubMed and EMBASE databases from inception to 
December 7, 2017 for randomized and non-randomized studies that included adults with previous 
venous thromboembolism requiring VKA interruption to undergo an elective procedure, and that 
reported venous thromboembolism or bleeding outcomes. Quality of evidence was graded by 
consensus. 
Results 
We included 28 cohort studies (20 being single-arm cohorts) with overall 6915 procedures for 
analysis. In 27 studies reporting perioperative venous thromboembolism outcomes, the pooled 
incidence of recurrent venous thromboembolism with bridging was 0.7% (95% confidence interval 
[CI] 0.4-1.2%) and 0.5% (95% CI 0.3-0.8%) without bridging. Eighteen studies reported major and/or 
non-major bleeding outcomes. The pooled incidence of any bleeding was 3.9% (95% CI 2.0-7.4%) 
with bridging and 0.4% (95% CI 0.1-1.7%) without bridging. In bridged patients at high 
thromboembolic risk, the pooled incidence for venous thromboembolism was 0.8% (95% CI 0.3-2.5) 
and 7.5% (95% CI 3.1-17.4%) for any bleeding. Quality of available evidence was very low, primarily 
due to a high risk of bias of included studies. 
Conclusions 
Periprocedural bridging increases the risk of bleeding compared to VKA interruption without 
bridging, without a significant difference in periprocedural venous thromboembolism rates.   
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Introduction  
Among >6 million individuals in the US who are on chronic anticoagulation, about 250,000 
patients each year need to temporarily interrupt their anticoagulants before an invasive procedure 
to diminish the risk of excess periprocedural bleeding.1 Despite the rapid adoption of direct oral 
anticoagulants (DOACs) in recent years, vitamin K antagonists (VKAs) remain the most frequently 
prescribed anticoagulants in the US and worldwide.2, 3 VKAs must be interrupted several days prior 
to a procedure to allow for regeneration of vitamin K dependent coagulation factors and subsequent 
normalization of coagulation.1 Because of the concern of an increased risk of thromboembolism 
during VKA interruption, periprocedural bridging with short-acting parenteral anticoagulants has 
been recommended for individuals at high thromboembolic risk.1, 4  
 A previous systematic review investigated periprocedural bridging in patients on VKAs for 
any indication and found an increased bleeding risk in bridged compared to non-bridged patients 
without a difference in thromboembolic risk.5 Similarly, a randomized trial of atrial fibrillation 
patients showed no difference in thromboembolic outcomes, but a significantly higher incidence of 
major bleeding with bridging compared with placebo.6 However, less is known about the risks and 
benefits of bridging in patients anticoagulated for venous thromboembolism. A recent retrospective 
study found an increased bleeding risk with bridging, but no substantial risk of recurrent venous 
thromboembolism without bridging, irrespective of estimated thromboembolic risk,7 suggesting that 
current guidelines fail to identify patients with high enough thromboembolic risk to justify bridging. 
To better define risks and benefits of bridging in patients with previous venous 
thromboembolism requiring VKA interruption to undergo an elective invasive procedure, we 
performed a systematic review comparing recurrent venous thromboembolism and bleeding 
outcomes with and without periprocedural bridging. 
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Methods 
We conducted this systematic review according to the protocol registered on PROSPERO 
(registration number CRD42017074710), and reporting conformed to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) statement.8  
Data Sources and Searches 
We performed a systematic literature review of articles in PubMed and EMBASE, from 
inception to December 7, 2017, without language restrictions (Supplemental Methods 1). We also 
considered conference proceedings, and screened bibliographies of retrieved articles, the most 
recent American College of Chest Physicians (ACCP) guidelines, and two previous systematic reviews 
on periprocedural anticoagulation.1, 5, 9 We searched for unpublished literature in the 
ClinicalTrials.gov and International Clinical Trials Registry Platform (ICTRP) databases.  
Study Selection 
We included original articles of randomized trials and observational studies that enrolled 
adults on long-term VKA therapy for secondary prophylaxis of venous thromboembolism who 
required anticoagulation interruption to undergo elective invasive procedures. Studies were eligible 
for inclusion if they assessed venous thromboembolism and/or bleeding outcomes in patients with 
or without heparin bridging; single-arm studies were also considered. Studies that did not 
specifically report outcomes for the population of interest or studies including <10 venous 
thromboembolism patients were excluded. Two physicians (C.B. and I.d.K.) independently screened 
titles and abstracts for eligibility, and in a second step, full-text articles of references selected in the 
first screening phase were screened (Figure 1). Disagreement was resolved by discussion. Non-
English articles were translated by native speakers.  
Data Extraction and Quality Assessment 
We extracted pre-specified data on study design, population characteristics, 
thromboembolic risk, invasive procedures, anticoagulation management strategies, and study 
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sponsors. In the absence of a universally accepted definition,1 bridging was classified as receipt of 
prophylactic, intermediate, or therapeutic doses of any heparin in the perioperative period. Data on 
patients who continued VKA perioperatively were not included, because our research question 
related to patients who required interruption of anticoagulation. The primary outcome was 
recurrent venous thromboembolism including deep vein thrombosis and pulmonary embolism (as 
ascertained by the individual studies) within 30 days postoperatively.10 Other follow-up periods were 
used if 30-day outcomes were not reported, as done previously.11 Secondary outcomes included 
major bleeding (according to the definition used in the individual studies), and any major and non-
major bleeding. Outcome data were extracted by two independent investigators. If outcomes were 
not specifically reported for the population of interest, we contacted study authors to request the 
information; 3 authors provided additional data.12-14  
Two independent reviewers (C.B. and I.d.K) assessed individual study quality using criteria 
adapted from the ACCP Antithrombotic Therapy and Prevention of Thrombosis, 9th edition;5, 15 this 
approach was chosen because it is applicable to single-arm studies. Items to assess quality of 
observational studies included consecutive enrollment, the existence of a study protocol prior to 
enrolment, the similarity of the setting and time frame of intervention and control groups, blinded 
outcome assessment, and loss to follow-up.5, 15 Nonrandomized studies were considered to be at 
high risk of bias and were downgraded to moderate risk if the study accounted for and reported all 
of the quality elements. On the other hand, they were upgraded to very high risk if they used a 
single-arm cohort design,16 or if there were severe or multiple problems with these elements.16  
Data Synthesis and Analyses 
All studies were qualitatively synthesized and comprehensively presented in tables depicting 
study characteristics and main findings. Meta-analysis to obtain a summary relative risk estimate 
was not supported because of the observational design of all included studies with reporting of 
unadjusted results, the high number of single-arm cohorts, and the large clinical heterogeneity 
across studies. We calculated pooled incidence of venous thromboembolism, major bleeding, and 
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any bleeding in procedures with and without bridging using a logistic-normal random-effects 
model.17 One study used propensity score matching and weighting to compare outcomes in patients 
with and without bridging; this resulted in some non-integer numbers of outcome events in the non-
bridging group, which were rounded to the next integer to calculate pooled incidences. In a 
sensitivity analysis, we rounded in the other direction. We also conducted pre-specified sensitivity 
analyses excluding conference abstracts or small studies (<100 procedures). Additional (not 
prespecified) sensitivity analyses were conducted: 1) excluding studies that did not specifically 
report outcomes for patients with prior venous thromboembolism, but could be included because 
no study patient experienced an outcome event, and 2) excluding a study18 that used propensity 
score matching and weighting to equalize the number of patients in the exposure groups. 
Predefined subgroup analyses were conducted according to baseline thromboembolic risk and 
heparin dose used (therapeutic vs. prophylactic). All analyses were performed with Stata 14 (Stata, 
College Station, TX, USA). 
Two investigators (C.B. and M.C. F.) rated the overall quality of evidence for 
thromboembolic and bleeding outcomes using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) methodology.19  
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Results 
Our search yielded 4,349 records after removal of duplicates. We excluded 4,110 records 
based on title and abstract and then assessed 239 full texts for eligibility, of which 28 studies met 
our inclusion criteria (Figure 1). Included studies reported results of overall 6,915 procedures, and 
individual study size varied between 10 and 2670 procedures (Supplemental Table 1).  
Of all included studies, 19 were prospective and 9 retrospective cohort studies, and none of 
them was a randomized trial comparing bridging and VKA interruption without bridging. Study 
characteristics are shown in Table 1 and Supplemental Table 1. Two records were conference 
abstracts, and 26 were published full text articles. All but 5 studies enrolled patients with different 
indications for anticoagulation including atrial fibrillation and mechanical heart valves, and among 
those we extracted only the specific data on patients with previous venous thromboembolism. Thus, 
specific information on demographics for this subgroup was mostly missing. Baseline 
thromboembolic risk was assessed in 21 studies using varying risk classifications schemes. Most 
studies included patients at any thromboembolic risk (n=15), while 1 included only low risk and 5 
only moderate to high risk patients. The decision to administer bridging anticoagulation was at the 
discretion of the provider in 11 studies and based on assessment of baseline thromboembolic risk in 
6 studies; in 5 studies, all patients requiring VKA interruption received bridging. Procedure types 
were reported in all but 1 study. 
Bridging strategies implemented in the different studies varied substantially (Table 2 and 
Supplemental Table 2). Most of the studies (n=22) defined bridging as administration of short-acting 
anticoagulants in both the pre- and postprocedural periods, while 2 studies also considered bridging 
that was administered in the preprocedural and 4 in the postprocedural periods only.   
 Overall quality of included studies was low (Supplemental Table 3). Only 8 studies compared 
outcomes in bridging and non-bridging groups, while the remaining were single-arm studies. All 
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studies reported results that were unadjusted for potential confounding except for Sjögren et al.,18 
where propensity score matching was used. 
Risk of Venous Thromboembolism 
All but one20 study reported venous thromboembolism outcomes in overall 6886 
procedures. Over a follow-up duration that varied from the time of postprocedural INR 
normalization to 180 days in the different studies, incidence of perioperative venous 
thromboembolism ranged from 0% to 4.4% with bridging (pooled incidence 0.7%, 95% confidence 
interval [CI] 0.4-1.2%) and from 0% to 2% without bridging (pooled incidence 0.5%, 95% CI 0.3-0.8%; 
Tables 3 and 4).  
The pooled incidence of venous thromboembolism in bridging and non-bridging groups 
remained similar in sensitivity analyses (Table 4). Among patients with high thromboembolic risk, we 
found a similar pooled incidence of perioperative venous thromboembolism events with bridging 
(pooled incidence 0.8%, 95% CI 0.3-2.5%). Only 1 study7 reported venous thromboembolism 
outcomes in high risk patients without bridging, and found 0 events in 21 procedures (Table 4). 
Incidence of venous thromboembolism was similar with therapeutic LMWH doses compared to 
prophylactic doses (pooled incidence 0.9% [95% CI 0.4-2.1%] and 1.4% [95% CI 0.5-4.4%], 
respectively), but the number of studies included in this subgroup analysis was limited (Table 4). 
Risk of Bleeding 
Data on major bleeding or any bleeding were available in 15 and 18 studies, respectively 
(Tables 3 and 4). Incidence of major bleeding as reported in included studies varied between 0% and 
5.6% for patients with bridging (pooled incidence 1.8%, 95% CI 1.2-2.5%), while it was generally 
lower in patients without bridging, ranging from 0% to 1.6% (pooled incidence 0.4%, 95% CI 0.1-
1.5%; Tables 3 and 4). Results were similar in sensitivity analyses (Table 4). Therapeutic LMWH 
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doses resulted in a similar pooled incidence of major bleeding compared to prophylactic doses (2.6% 
[95% CI 1.4-4.7%] and 2.1% [95% CI 0.8-5.5%]), but the number of studies was low. 
Incidence of any major and non-major bleeding differed even more considerably between 
the bridging and non-bridging groups, with a pooled incidence of 3.9% (95% CI 2.0-7.4%) and 0.4% 
(95% CI 0.1-1.7%), respectively (Table 3 and 4).  
Quality of Overall Evidence 
 The quality of the overall body of evidence for the association of periprocedural bridging 
with venous thromboembolism, major bleeding and any bleeding was very low (Supplemental Table 
4). All included studies had an observational design with a very high risk of bias. Also, we assumed 
publication bias to be substantial for all outcomes, because some studies that did not separately 
report outcomes for our specific population of interest could not be included in our systematic 
review (Figure 1), and a search in clinical trial registries yielded two studies without published results 
that potentially met inclusion criteria.   
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Discussion 
This systematic review showed that periprocedural bridging in patients with previous venous 
thromboembolism considerably increases bleeding risk compared to VKA interruption without 
bridging, without resulting in differences of venous thromboembolic outcomes. Our results suggest 
that most venous thromboembolism patients will not benefit from bridging. However, the quality of 
the available evidence on the risks and benefits of periprocedural bridging in this population is low.  
Our results show substantial differences in the definition and management of 
periprocedural bridging across studies. However, no specific bridging strategy or dosing regimen has 
proven to be superior.4 To date, no randomized study has shown a clear benefit of periprocedural 
bridging for patients on long-term anticoagulants, while the bulk of available data suggests an 
increased bleeding risk with bridging. A recent randomized trial found that foregoing bridging was 
not associated with an increased risk of arterial thromboembolic events but conferred a significant 
reduction in major bleeding in patients with atrial fibrillation requiring periprocedural warfarin 
interruption.6 Another trial comparing bridging with continued anticoagulation in patients 
undergoing cardiac device surgery similarly found a 3- to 4-fold  higher bleeding risk with bridging.23 
A systematic review that assessed periprocedural bridging in patients with any indication for 
anticoagulation concluded that overall and major bleeding was increased in patients with bridging 
compared to those without, while the risk of thromboembolism did not differ.5 However, the low 
quality of included studies precluded firm conclusions about risks and benefits of bridging 
particularly for high risk patients, similar to our study. No previous or ongoing trial investigated 
bridging in patients with previous venous thromboembolism.   
Evaluation of patient- and procedure-related risk factors for thromboembolism and bleeding 
as well as estimation of clinical consequences of these potential adverse events is needed to 
determine the optimal perioperative anticoagulation management in patients on chronic VKA 
therapy.43 An increasing evidence base suggests that VKAs can be safely continued in a number of 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
procedures with low bleeding risk.6, 22, 23, 44 More uncertainty exists about periprocedural 
management strategies in non-minimal bleeding risk procedures, where anticoagulation interruption 
is needed. While arterial thromboembolic events in patients with mechanical heart valves or atrial 
fibrillation are related to a substantial 15-70% risk of disability and death which outweighs mortality 
risks of major bleeding events 2 to 10-fold,43, 45, 46 the case-fatality of recurrent venous 
thromboembolism (5-13%) and major bleeding events (8-10%) are more similar.43, 47 Therefore, the 
number of major bleeding events that would theoretically be acceptable to prevent one 
thromboembolic event is substantially lower for patients with previous venous thromboembolism 
compared to patients anticoagulated for prevention of arterial thromboembolic events, so the 
threshold to provide treatments that increase the risk of major bleeding should be higher for venous 
thromboembolism patients. Our results suggest that bridging exposes these patients to a markedly 
higher bleeding risk and should therefore not be used if thromboembolic risk is low or moderate. 
Based on the available evidence, admittedly of low quality, a potential benefit of bridging has not 
been established even in patients at high thromboembolic risk.  
Periprocedural bridging continues to be overused in patients with previous venous 
thromboembolism, mainly because of overestimation of thromboembolic risk,7, 48 reflecting the 
uncertainty about the role of bridging and the assessment of baseline thromboembolic risk. Efforts 
to standardize anticoagulation management in the periprocedural setting and high quality studies to 
further clarify the efficacy and safety of bridging in patients at high risk of venous thromboembolism 
are needed to optimize their care. Although VKAs continue to be the most frequently prescribed oral 
anticoagulants,2 the role of bridging, if any, will further diminish with the increased use of DOACs.4, 49 
The shorter half-life of DOACs, which limits the duration of preprocedural anticoagulation 
interruption, and their rapid time-to-onset obviate the need of periprocedural bridging.4, 43, 49 Only 
few observational studies and substudies of randomized trials investigated periprocedural 
management strategies in patients on DOACs, and did not find a benefit of bridging in this 
population.50, 51   
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To our knowledge, this is the first study systematically assessing available literature on the 
risks and benefits of periprocedural bridging in the specific population of patients with previous 
venous thromboembolism. Another strength of this study includes the rigorous search for available 
data, without language restriction and with consideration of unpublished articles.  
The results of our systematic review need to be interpreted in the context of several 
limitations. First, overall quality of included studies was low: all included studies were non-
randomized and many of them lacked a comparison group. Second, most studies included a 
heterogeneous population of patients at high and low thromboembolic risk and procedures at 
varying degrees of bleeding risk, yielding difficult to interpret results that are likely affected by 
confounding by indication, as patients at high thromboembolic risk might be more likely to receive 
bridging compared to non-high risk patients. Third, some studies did not specifically report 
outcomes for patients with previous venous thromboembolism and could thus not be included in 
our systematic review (Figure 1), potentially resulting in publication bias. Fourth, follow-up duration 
differed between studies, and although we calculated pooled incidences of perioperative outcome 
events, these incidences might differ if follow-up duration in included studies were more 
homogeneous. Finally, the definition of major bleeding and ascertainment of thromboembolic 
events was not uniform across studies, which may have limited the reliable estimation of pooled 
outcome incidences.  
In conclusion, our systematic review showed that patients at low and moderate 
thromboembolic risk do not benefit from periprocedural bridging because of a considerably 
increased risk of bleeding associated with bridging compared to VKA interruption without bridging, 
while the risk of periprocedural thromboembolic events was similar with or without bridging.   
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Figure Legend. Study flow diagram. Studies evaluated for inclusion, adapted from PRISMA 
Statement Flow Diagram.8 Abbreviations: VKA, vitamin K antagonist.  
* Until December 7, 2017 
† identified through searching of bibliographies and clinical trial databases 
‡ refers to duplicate publication (e.g. conference abstract) or studying the same population as 
another publication 
§ because abstract/publication was not available and results could not be obtained from authors, or 
study was still ongoing 
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Table 1. Characteristics of Included Studies 
 
Characteristic  Studies, n (%) 
Design and Setting   
Study design Randomized controlled trial 0* 
 Cohort, prospective 19 (68) 
 Cohort, retrospective 9 (32) 
 Single-arm studies 20 (71) † 
Year of Publication Before 2010 12 (43) 
 2010 and later 16 (57) 
Publication Type Full text article 26 (93) 
 Conference abstract 2 (7) 
Study sponsors Industry 5 (18) 
 Non-profit 7 (25) 
 Not reported 16 (57) 
Geographical region North America 11 (39) 
 South America 1 (4) 
 Europe 11 (39) 
 Asia  1 (4) 
 Australia 2 (7) 
 Not reported 2 (7) 
Number of study sites Single center 14 (50) 
 Multicenter 10 (36) 
 Not reported 4 (14) 
Treatment setting Outpatients only  4 (14) 
Population   
% of patients with previous venous thromboembolism 0-19% 10 (36) 
 20-99% 13 (46) 
 100% 5 (18) 
Thromboembolic risk of included patients Any risk 15 (54) 
 Only low risk 1 (4) 
 Only moderate to high risk 5 (18) 
 No risk stratification performed 7 (25) 
Reason for VKA interruption Antiarrhythmic device surgery 2 (7) 
 Dental procedures 1 (4) 
 Only minor surgeries or procedures 4 (14) 
 Minor and major surgeries/procedures 20 (71) 
 Unclear  1 (4) 
Indication for bridging At the discretion of the provider 11 (39) 
 Strictly based on thromboembolic risk 6 (21) 
 All patients requiring VKA interruption 5 (18) 
 Random assignment 2 (7) ‡ 
 Only inpatients 1 (4) 
 unclear 3 (11) 
Abbreviations: INR, international normalized ratio; VKA, vitamin K antagonist. 
*three studies were designed as randomized controlled trials comparing bridging to continued VKA 
or comparing two different bridging strategies. We considered these studies as prospective cohorts 
for our study because none of these trials compared bridging and VKA interruption without bridging.   
† among all prospective and retrospective cohort studies 
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‡ patients were randomly assigned to bridging or continuation of VKA in two studies, but none used 
random assignment to bridging vs. VKA interruption without bridging 
§ Some studies implemented multiple strategies 
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Table 2. Periprocedural Anticoagulation Management 
Management Strategy* Studies, n (%) 
Periprocedural Bridging Pre- and postprocedural  22 (79) 
 Only preprocedural 2 (7) 
 Only postprocedural 4 (14) 
 Not specified 4 (14) 
Type of bridging anticoagulant LMWH 28 (100) 
 Unfractionated heparin 6 (21) 
Dosing of bridging anticoagulant Therapeutic 18 (64) 
   Sub-therapeutic 9 (32) 
 Prophylactic 16 (57) 
 Not reported 1 (4) 
Preprocedural Management   
VKA interruption, days 6 7 (25) 
 5 19 (68) 
 4 9 (32) 
   not reported 3 (11) 
Last dose of LMWH, hours < 12 1 (4) 
 12-23 13 (46) 
 24 7 (25) 
 NA (only postop bridging) 2 (7) 
 Not reported 6 (21) 
Postprocedural Management   
Restart of LMWH, hours 0-23 16 (57) 
 24 7 (25) 
 Not specifically reported 7 (25) 
Restart of VKA, hours Evening of procedure 10 (36) 
 Day after procedure 18 (64) 
 2 or more days after procedure 4 (14) 
 Not reported 6 (21) 
Initial dosing of VKA Maintenance dose 9 (32) 
 Loading dose 3 (11) 
 Not reported 16 (57) 
Duration of bridging Prespecified no. of days 2 (7) 
 Until INR therapeutic 12 (43) 
 Until INR therapeutic on 2 consecutive days 5 (18) 
 Not reported 9 (32) 
Abbreviations: INR, international normalized ratio; LMWH, low molecular weight heparin; VKA, 
vitamin K antagonist. 
* Some studies implemented multiple strategies 
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Table 3. Venous Thromboembolism and Bleeding Outcomes 
 
  Bridging No Bridging 
Study Follow-up 
Duration 
Venous 
thromboembolism/ 
Procedures, n (%) 
Major Bleeding/ 
Procedures, n (%) 
Any Bleeding ||/ 
Procedures, n (%) 
Venous 
thromboembolism/ 
Procedures, n (%) 
Major Bleeding/ 
Procedures, n (%) 
Any Bleeding ||/ 
Procedures, n (%) 
Ahmed, 2010
21
 8 weeks 0/12 (0) NA 1/12 (8.3) 0/5 (0) NA 0/5 (0) 
Bajkin, 2009
22
* 30d 0/19 (0) NA not clear - - - 
Birnie, 2013
23
* not clear 0/16 (0) NA not clear - - - 
Breen, 2016
24
 30d 0/29 (0)
 
not clear
 
6/29 (20.7) - - - 
Burbury, 2011
25
* 6 weeks - - - 0/39 (0) not clear not clear 
Clark, 2015
7
 30d 0/555 (0) 12/555 (2.2) 15/555 (2.7) 3/1257 (0.2) 2/1257 (0.2) 2/1257 (0.2) 
Constans, 2007
42
* 90d 0/10 (0) not clear not clear - - - 
Douketis, 2005
20
 until INR 2-3 NA 0/21 (0) 0/21 (0) - - - 
Dunn, 2007
26
 28d 1/96 (1.0) not clear not clear - - - 
Eisele, 2012
27
* not clear 0/69 (0) NA not clear - - - 
Fernandez, 2009
28
* 30d 0/24 (0) not clear not clear 0/14 (0) 0/14 (0) 0/14 (0) 
Garcia, 2008
29
 30d 0/22 (0) not clear not clear 2/179 (1.1) 0/179 (0) 0/179 (0) 
Hammerstingl, 2009
30
* not clear 0/10 (0) 0/10 (0) 0/10 (0) - - - 
Hwang, 2017
31
* 30d 0/34 (0) not clear not clear - - - 
Jaffer, 2005
32
 30d 0/18 (0) 1/18 (5.6) 1/18 (5.6) - - - 
Klamroth, 2010
12
 28d 0/63 (0) 0/63 (0) † 0/63 (0) † - - - 
Majluf-Cruz, 2011
33
 not clear 2/152 (1.3) 4/152 (2.6) 26/152 (17.1) - - - 
Malato, 2010
34
 30d 2/45 (4.4) 1/45 (2.2) 1/45 (2.2) - - - 
McBane, 2010
13
 90d 4/342 (1.2) † 9/342 (2.6) † 24/342 (7.0) † 3/152 (2.0) † 1/152 (0.7) † 3/152 (2.0) † 
Pengo, 2009
14
 30d 2/210 (1.0) 1/210 (0.5) † 9/210 (4.3) † - - - 
Saccullo, 2012
35
 30d 2/52 (3.8) not clear not clear - - - 
Santamaria, 2013
36
* 90d 0/10 (0) not clear not clear - - - 
Sjögren, 2017
18
 30d 10/1331 (0.8) NA 10/1331 (0.8) 5.5/1331 (0.4) ‡
 
NA 2.1/1331 (0.2) ‡ 
Skeith, 2012
37
 90d 2/152 (1.3) 2/152 (1.3) 6/152 (3.9) 2/482 (0.4) 8/482 (1.6) 16/482 (3.3) 
Spyropoulos, 2004
38
 60d 0/45 (0) 0/45 (0) 2/45 (4.4) - - - 
Spyropoulos, 2006
39
* 30d 0/22 (0) § not clear not clear - - - 
Wilson, 2001
40
 90d 0/26 (0) 0/26 (0) 0/26 (0) - - - 
Wiszniewsky, 2011
41
 180d 0/63 (0) 0/63 (0) 13/63 (20.6) - - - 
Abbreviations: NR, not available because outcome was not assessed in study.  
*these studies did not specifically report venous thromboembolism outcomes by indication for 
anticoagulation (i.e. patients with previous venous thromboembolism), but were included because 
the number of outcome events was 0 for all indications 
† personal communication by the authors 
‡ patients not receiving bridging anticoagulation were propensity score matched and weighted to 
equal the number of patients who received bridging 
§ the number of venous thromboembolic events in subgroup of patients with a previous venous 
thromboembolism could only be identified in the 22 patients who received unfractionated heparin 
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|| includes major bleeding and any other bleeding outcome that was specifically reported for 
patients with previous venous thromboembolism 
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Table 4. Pooled Incidence of Venous Thromboembolism and Bleeding Outcomes  
 
 Any Outcome Venous Thromboembolism Major Bleeding All Bleeding* 
Group 
Studies, 
n 
Procedures, 
n 
Studies, 
n 
Events/ 
Procedures, 
n 
Pooled 
incidence, % 
(95% CI) 
Studies, 
n 
Events/ 
Procedures, 
n 
Pooled 
incidence, % 
(95% CI) 
Studies, 
n 
Events/ 
Procedures, 
n 
Pooled 
incidence, % 
(95% CI) 
Main Analysis            
All studies 28 6915† 27 40.5 / 6886  15 41 / 3786  18 137.1/ 6494  
   With bridging 27 3448 26 25 / 3427 0.7 (0.4-1.2) 13 30 / 1702 1.8 (1.2-2.5) 16 114 / 3074 3.9 (2.0-7.4) 
   Without bridging 8 3459 8 15.5 / 3459 0.5 (0.3-0.8)‡ 5 11 / 2084 0.4 (0.1-1.5) 7 23.1 / 3420 0.4 (0.1-1.7)§ 
Sensitivity analyses             
Excluding studies without 
specific outcome reporting 
for population of interest || 18 6648† 17 40.5 / 6619  11 41 / 3557  14 137.1/ 6265  
   With bridging 18  3234 17 25 / 3213 0.8 (0.5-1.3) 11 30 / 1666 1.8 (1.3-2.6) 14 114 / 3038 4.4 (2.3-8.2) 
   Without bridging 6 3406 6 15.5 / 3406 0.5 (0.3-0.8)‡ 3 11 / 1891 0.5 (0.1-2.0) 5  23.1 / 3227 0.6 (0.1-2.4)¶ 
Excluding conference 
abstracts 26 6725† 25 38.5 / 6696  13 37 / 3620  16 111.1/ 6328  
   With bridging 25 3272 24 23 / 3251 0.7 (0.4-1.2) 12 26 / 1550 1.6 (0.8-3.2) 15 88 / 2922 3.4 (1.8-6.6) 
   Without bridging 7 3445 7 15.5 / 3445 0.5 (0.3-0.8)‡ 4 11 / 2070 0.4 (0.1-1.6) 6 23.1 / 3406 0.4 (0.1-1.8)** 
Excluding Sjögren, et al. † 27 4245 26 25 / 4224  15 41 / 3832  17 125 / 3878  
   With bridging 26 2117 25 15 / 2096 0.6 (0.3-1.3) 13 30 / 1702 1.8 (1.2-2.5) 15 104 / 1743 4.9 (2.7-8.7) 
   Without bridging 7 2128 7 10 / 2128 0.5 (0.2-1.2) 5 11 / 2084 0.4 (0.1-1.5) 6 21 / 2089 0.6 (0.1-2.8) 
Excluding studies with <100 
procedures 7 6173† 7 35.5 / 6165  6 39 / 3481  7 113.1/ 6143  
   With bridging 7 2764 7 20 / 2764 0.7 (0.4-1.2) 5 28 / 1411 2.0 (1.4-2.9) 6 90 / 2742 4.0 (1.8-8.7) 
   Without bridging 5 3401 5 15.5 / 3401 0.5 (0.3-0.8)‡ 4 11 / 2070 0.4 (0.1-1.6) 5 23.1 / 3401 0.5 (0.1-1.9) 
Subgroup analyses            
High thromboembolic risk †† 9 394 9 3 / 394     7 45 / 361  
   With bridging 9 373 9 3 / 373 0.8 (0.3-2.5) NA NA NA 7 44 / 340 7.5 (3.1-17.4) 
   Without bridging 1 21 1 0 / 21 NA NA NA NA 1 1 / 21 NA 
LMWH dose ††            
   Therapeutic dose 11 981 10 5 / 580 0.9 (0.4-2.1) 4 10 / 387 2.6 (1.4-4.7) 6 35 / 800 3.9 (2.0-7.5) 
   Prophylactic dose 6 362 5 3 / 208 1.4 (0.5-4.4) 3 4 / 188 2.1 (0.8-5.5) 4 32 / 342 4.4 (0.9-18.3) 
* includes major bleeding and any other bleeding outcomes that were specifically reported for 
patients with previous venous thromboembolism 
† in the study by Sjögren et al,18 procedures in the non-bridging group were propensity score 
matched and weighted to equal the number of procedures in the bridging group; therefore, the 
number of procedures with bridging and without bridging does not add up to the exact number of 
overall procedures 
‡ the non-integer number of outcome events (5.5 venous thromboembolic events) in the study by 
Sjögren et al was rounded to the next integer for this analysis. When rounding down to the next 
lower integer, the results were similar (pooled incidence 0.4%, 95%CI 0.3-0.7%) 
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§ the non-integer number of outcome events (2.1 events of any bleeding) in the study by Sjögren et 
al was rounded to the next integer for this analysis. When rounding up to the next higher integer, 
the results were similar (pooled incidence 0.5%, 95%CI 0.1-1.8%) 
||some studies did not report results separately for patients with prior venous thromboembolism 
and could only be included because there were no venous thromboembolism 22, 23, 25, 27, 28, 30, 31, 36, 39, 42 
or bleeding28-30, 40 outcomes in the overall population. As this might bias our study sample to studies 
with a low number of outcome events, we excluded these studies for this subgroup analysis. 
¶ the non-integer number of outcome events (2.1 events of any bleeding) in the study by Sjögren et 
al was rounded to the next integer for this analysis. When rounding up to the next higher integer, 
the results were similar (pooled incidence 0.7%, 95%CI 0.2-2.4%) 
** the non-integer number of outcome events (2.1 events of any bleeding) in the study by Sjögren et 
al was rounded to the next integer for this analysis. When rounding up to the next higher integer, 
the results were similar (pooled incidence 0.5%, 95%CI 0.1-1.9%) 
†† for these analyses, we included only studies that reported outcomes separately for the specific 
subgroup of interest 
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Supplemental Methods 1. Data Sources and Search Strategy 
The PubMed and Embase databases were searched from inception to December 7, 2017, for 
published articles in any language on the association between periprocedural anticoagulation 
management (bridging with short acting anticoagulants vs. no bridging) in adults on chronic 
anticoagulation treatment with vitamin K antagonists (VKA) for secondary prevention of venous 
thromboembolism who required interruption of VKA for an invasive elective procedure. Following 
search strategy was implemented in PubMed: 
(((((((((((((temporary[tw] OR temporarily[tw]) AND (discontinue[tw] OR discontinuous[tw] OR 
discontinuation[tw])) OR management[tw] OR ((anticoagulation[tw] OR anticoagulant[tw] OR 
anticoagulants[tw] OR anticoagulate[tw] OR anti-coagulation[tw] OR anti-coagulant[tw] OR anti-
coagulants[tw] OR anti-coagulate[tw]) AND (interrupt[tw] OR interrupted[tw] OR interruption[tw] 
OR bridge[tw] OR bridging[tw] OR wean[tw] OR weaned[tw] OR weaning[tw] OR taper[tw] OR 
tapers[tw] OR tapered[tw] OR tapering[tw] OR suspend[tw] OR suspended[tw] OR suspending[tw] 
OR suspension[tw] OR cease[tw] OR ceased[tw] OR ceasing[tw] OR cessation[tw] OR cessations[tw] 
OR ceasing[tw] OR stop[tw] OR stopping[tw] OR stops[tw] OR stopped[tw]) AND (operative OR 
operation OR operate OR operatively OR surgery[tw] OR surgeries[tw] OR surgical[tw] OR 
surgically[tw] OR procedure[tw] OR procedures[tw] OR procedural[tw] OR preoperative[tw] OR pre-
operative[tw] OR perioperative[tw] OR peri-operative[tw])) OR Bridging[tw])))))))))  
AND  
((("Surgical Procedures, Operative"[Mesh] OR "Operative Surgical Procedure" OR "Operative Surgical 
Procedures" OR "Operative Procedures" OR "Operative Procedure" OR invasiv* OR procedur* OR 
"Post-operative Procedure" OR "Postoperative Procedure" OR "Post-operative Procedures" OR 
"Postoperative Procedures" OR "Pre-operative Procedure" OR "Preoperative Procedure" OR "Pre-
operative Procedures" OR "Preoperative Procedures" OR peri-procedural OR periprocedural OR peri-
procedure OR periprocedure OR "Preoperative Care"[Mesh] OR "Preoperative Care" OR "Pre-
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operative Care" OR "Intraoperative Care"[Mesh] OR "Intra-operative Care" OR "Intraoperative Care" 
OR "Postoperative Care"[Mesh] OR "Post-operative Care" OR "Postoperative Care" OR 
"Perioperative Care"[Mesh] OR "Peri-operative Care" OR "Perioperative Care" OR "Peroperative 
Care" OR "Per-operative Care" OR "perioperative period"[Mesh] OR peri-operative OR perioperative 
OR pre-operative OR preoperative OR post-operative OR postoperative)))))  
AND  
((("Venous Thrombosis"[Mesh] OR DVT OR VTE OR "venous thrombosis" OR "venous thromboses" 
OR "deep vein thrombosis" OR "deep vein thromboses" OR "pulmonary embolus" OR "pulmonary 
emboli" OR "pulmonary embolism" OR “thromboembolism” OR “thromboembolic”)))  
AND 
((("Anticoagulants/administration and dosage"[Mesh] OR "Anticoagulants/adverse effects"[Mesh] 
OR "Anticoagulants/therapeutic use"[Mesh] OR "Vitamin K/administration and dosage"[Mesh] OR 
"Vitamin K/adverse effects"[Mesh] OR "Vitamin K/agonists"[Mesh] OR "Vitamin K/antagonists and 
inhibitors"[Mesh] OR "Vitamin K/therapeutic use"[Mesh] OR "Vitamin K/therapy"[Mesh] OR 
"Warfarin/administration and dosage"[Mesh] OR "Warfarin/adverse effects"[Mesh] OR 
"Warfarin/therapeutic use"[Mesh] OR "Coumarins/administration and dosage"[Mesh] OR 
"Coumarins/adverse effects"[Mesh] OR "Coumarins/therapeutic use"[Mesh] OR "Factor Xa 
Inhibitors"[Mesh] OR "Heparin/administration and dosage"[Mesh] OR "Heparin/adverse 
effects"[Mesh] OR "Heparin/analogs and derivatives"[Mesh] OR "Heparin/therapeutic use"[Mesh] 
OR "Factor Xa Inhibitors"[Pharmacological Action] OR warfarin OR acenocoumarol OR 
phenprocoumon OR coumadin OR dicumarol OR phenindione OR "vitamin K antagonist" OR VKA OR 
dabigatran OR edoxaban OR rivaroxaban OR apixaban OR Heparin OR "Low-Molecular-Weight 
Heparin" OR "LMW heparin" OR UFH OR "unfractionated heparin" OR Dalteparin OR Enoxaparin OR 
Nadroparin OR Tinzaparin)))This search strategy was adapted for searching the Embase database.  
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We also searched for unpublished articles by reviewing guidelines1 and previous systematic 
reviews on periprocedural anticoagulation,2, 3 screening of bibliographies of retrieved articles, and 
searching in the ClinicalTrials.gov and the International Clinical Trials Registry Platforms (ICTRP) 
databases. 
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Supplemental Table 1. Characteristics of Included Studies, by Individual Study 
Study Study Design Setting Study Population and VTE 
risk; % Previous VTE in 
Overall Study Population 
Indication for 
Bridging 
Planned Invasive 
Procedure 
Intervention / 
Control 
Proce-
dures, n 
Study 
Sponsor 
Ahmed, 2010 Cohort, 
retrospective 
1 teaching hospital, 
Minnesota, USA 
VTE risk NR; 8%  At the discretion of 
the provider 
Anti-arrhythmic 
device surgery 
I: LMWH, UFH 
C: no bridging 
I: 12 
C: 5 
Non-
profit 
Baijkin, 2009 Cohort, 
prospective* 
1 oral surgery 
clinic, Serbia 
VTE risk NR; 16% Random 
assignment  
Simple extraction of 
1 tooth 
I: LMWH 
C: continued VKA† 
I: 19 
C: 15† 
NR 
Birnie, 2013 Cohort, 
prospective* 
17 centers in 
Canada, 1 in Brazil 
moderate to high VTE risk; 
5% 
Random 
assignment 
Antiarrhythmic 
device surgery 
I: LMWH, UFH 
C: continued VKA† 
I: 16 
C: 21† 
Non-
profit 
Breen, 2013 Cohort, 
retrospective 
1 tertiary care 
hospital, Australia 
Patients who received 
LMWH bridging, any VTE risk; 
27% 
At the discretion of 
the provider 
Various major and 
minor procedures 
I: LMWH 
C: - 
I: 29 
C: - 
NR 
Burbury, 2011 Cohort, 
prospective 
1 hospital, 
Australia 
on warfarin >6 weeks, any 
VTE risk; 22% 
At the discretion of 
the provider, based 
on VTE risk 
Various major and 
minor procedures 
I: LMWH 
C: no bridging 
I: 0 
C: 39 
NR 
Clark, 2015 Cohort, 
retrospective 
Integrated health 
care system, 
Colorado, USA 
any VTE risk; 100% At the discretion of 
the provider, based 
on therapy plans 
Various major and 
minor procedures 
I: short-acting 
anticoagulant  
C: no bridging 
I: 555 
C: 1257 
Non-
profit 
Constans, 
2007 
Cohort, 
prospective 
1 tertiary care 
hospital, Spain 
Adults requiring bridging due 
to endoscopy, any VTE risk; 
10% 
All study patients; 
probably all with 
VKA interruption 
Gastroscopy or 
colonoscopy 
I: LMWH 
C: -  
I: 10 
C: -  
NR 
Douketis, 2005 Cohort, 
prospective 
1 hospital, Canada Patients requiring bridging 
due to procedure, any VTE 
risk; 29% 
All study patients; 
reason for bridging 
decision unclear 
Various major and 
minor procedures 
I: LMWH 
C: - 
I: 21 
C: - 
NR 
Dunn, 2007 Cohort, 
prospective 
24 sites in North 
America 
Outpatients for whom 
bridging was planned, VTE 
risk NR; 37% 
At the discretion of 
the physician 
Various major and 
minor procedures  
I: LMWH 
C: -  
I: 96 
C: -  
Industry 
Eisele, 2012 Cohort, 
retrospective 
Multiple hospitals 
and physician 
offices, Germany 
Patients who received 
cetroparin bridging, VTE risk 
NR; 29% 
At the discretion of 
the physician 
Surgeries, 
endoscopy, 
angiography 
I: LMWH 
C: - 
I: 69 
C: - 
Industry 
Fernandez, 
2009 
Cohort, 
prospective 
NR Any VTE risk; 44% VTE <3 months ago 
and non-high 
bleeding risk 
procedure 
High and low 
bleeding risk 
procedures 
I: LMWH 
C: no bridging 
I: 24 
C: 14 
NR 
Garcia, 2008 Cohort, 101 physician Outpatients, any VTE risk; At the discretion of Outpatient I: LMWH I: 15 Industry 
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prospective practices, USA 14% the physician procedures C: no bridging C: 179 
Hammerstingl, 
2009 
Cohort, 
prospective 
Unclear, probably 
1 hospital, 
Germany 
Patients receiving bridging 
with therapeutic enoxaparin, 
VTE risk NR; 14% 
Not clear Minor surgery and 
invasive procedures 
I: LMWH 
C: - 
I: 10 
C: - 
NR 
Hwang, 2017 Cohort, 
retrospective 
1 tertiary care 
center, South 
Korea 
Referred to clinic for 
bridging, VTE risk NR; 70% 
At the discretion of 
the provider 
Various major and 
minor procedures 
I: LMWH 
C: - 
I: 34 
C: -  
Non-
profit 
Jaffer, 2005 Cohort, 
retrospective 
1 anticoagulation 
clinic, Ohio, USA 
High enough VTE risk to 
justify bridging; 26% 
Sufficiently high 
VTE risk 
Various major and 
minor procedures 
I: LMWH 
C: - 
I: 18 
C: -  
NR 
Klamroth, 
2010 
Cohort, 
prospective 
Unclear, probably 
1 hospital, 
Germany 
Any VTE risk; 32% All patients without 
contraindication to 
LMWH 
Major (75%) and 
minor surgeries 
I: LMWH 
C: - 
I: 63 
C: - 
NR 
Majluf-Cruz, 
2011 
Cohort, 
prospective 
NR Patients with recurrent VTE, 
high VTE risk, 100% 
All study patients 
(recurrent VTE) 
Various major and 
minor procedures 
I: LMWH 
C: rivaroxaban † 
I: 152 
C: 158† 
NR 
Malato, 2010 Cohort, 
prospective 
1 tertiary care 
center, Italy 
Outpatients, any VTE risk; 
14% 
All patients without 
contraindication to 
LMWH 
Various major and 
minor procedures 
I: LMWH 
C: - 
I: 45 
C: -  
NR 
McBane, 2010 Cohort, 
prospective 
1 tertiary care 
clinic, USA 
Referred for VKA 
management, any VTE risk; 
100% 
Moderate to high 
VTE risk patients 
Various major and 
minor procedures 
I: LMWH 
C: no bridging 
I: 342 ‡ 
C: 152 ‡ 
Non-
profit 
Pengo, 2009 Cohort, 
prospective 
22 anticoagulation 
centers, Italy 
Any VTE risk; 17% All requiring 
periprocedural VKA 
interruption 
Various high and low 
bleeding risk 
procedures 
I: LMWH 
C: - 
I: 210 
C: -  
Non-
profit 
Sacullo, 2012 Cohort, 
prospective 
1 tertiary care 
center, Italy 
Cancer patients on long-term 
VKA for whom bridging was 
planned, any VTE risk; 33% 
Indication unclear Major and minor 
surgery, chemo-
therapy induced 
thrombocytopenia 
I: LMWH 
C: - 
I: 52 
C: - 
NR 
Santamaria, 
2013 
Cohort, 
prospective* 
10 hospitals, Spain Outpatients, any VTE risk; 6% All patients 
requiring VKA 
interruption for 
outpatient surgery 
Outpatient surgical 
or invasive 
procedures 
I: LMWH or UFH 
C: - 
I: 10 
C: - 
Industry 
Sjögren, 2017 Cohort, 
retrospective 
Multiple health 
care centers, 
Sweden 
VTE risk NR; 41% At the discretion of 
the provider 
Indication for VKA 
interruption unclear 
I: LMWH 
C: no bridging 
I: 1331 
C: 1331 § 
Non-
profit 
Skeith, 2012 Cohort, 
retrospective 
1 medical center, 
Canada 
Patients with VTE events >3 
months ago; 100% 
Patients requiring 
postinterventional 
inpatient 
treatment  
Various major and 
minor procedures 
I: LMWH 
C: no bridging 
I: 152  
C: 482 
NR 
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Spyropoulos, 
2004 
Cohort, 
retrospective 
Integrated health 
care system, USA 
Patients receiving bridging, 
any VTE risk; 36% 
At the discretion of 
the provider 
Various major and 
minor procedures 
I: LMWH 
C: - 
I: 45 
C: - 
NR 
Spyropoulos, 
2006 
Cohort, 
prospective 
14 centers, USA 
and Canada 
On VKA for 3 months, on 
perioperative heparin for 2 
d, any VTE risk; 12% 
At the discretion of 
the provider 
Various major and 
minor procedures 
I: LMWH or UFH 
C: -  
I: 22 || 
C: - 
Industry 
Wilson, 2001 Cohort, 
prospective 
1 anticoagulation 
clinic, Canada 
Referred to clinic, high VTE 
risk; 55% 
High VTE risk Various major and 
minor procedures 
I: LMWH 
C: - 
I: 26 
C: - 
NR 
Wiszniewsky, 
2011 
Cohort, 
prospective 
1 clinic, Poland Thrombophilia or APS, high 
to very high VTE risk; 100% 
High and very high 
VTE risk 
Various major and 
minor procedures 
I: LMWH 
C: - 
I: 63 
C: - 
NR 
Abbreviations: APS, antiphospholipid antibody syndrome; LMWH, low molecular weight heparin; UFH, unfractionated heparin; VKA, vitamin K 
antagonist; VTE, venous thromboembolism.  
*these studies were designed as randomized controlled trials comparing bridging to continued VKA or comparing two different bridging 
strategies. We considered these studies to be prospective cohorts for our systematic review, because none of these trials compared bridging and 
VKA interruption without bridging.   
† patients with continued anticoagulation during surgery or received periprocedural bridging with direct oral anticoagulants did not meet the 
inclusion criteria for our systematic review and were therefore not further considered for our analyses 
‡ personal communication by the investigator 
§ comparison group was propensity score matched and weighted; actual overall number of patients with previous VTE was 2670 in the bridging 
and non-bridging group combined. 
|| Outcomes for patients with previous VTE were only available for patients in the group of patients who received UFH (rather than LMWH)  
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Supplemental Table 2. Periprocedural Anticoagulation Management, by Individual Study 
   Preoperative Management Postoperative Management 
Study Peri-
procedural 
Bridging 
Type of 
Bridging 
Anticoagulant 
VKA 
Interruption, 
d 
Dosing of Bridging 
Anticoagulant 
Last Dose of 
LMWH, h 
Restart of 
LMWH, h 
Restart of VKA Initial Dosing 
of VKA 
Stop of Bridging 
Ahmed, 2010 Pre/post LMWH, UFH 3-5 therapeutic 12-18 24 Evening of 
procedure 
NR When INR 
therapeutic 
Baijkin, 2009 Pre/post LMWH 3-4 Prophylactic or 
subtherapeutic 
 12 Evening of 
procedure 
Evening of 
procedure 
NR When INR 
therapeutic 
Birnie, 2013 Pre/post LMWH, UFH 5 therapeutic >24 24 Evening or morning 
after procedure 
At 
investigator’s 
discretion 
When INR 
therapeutic 
Breen, 2013 Pre/post LMWH 5 Low or 
therapeutic 
Day prior  At provider’s 
discretion 
At provider’s 
discretion 
NR NR 
Burbury, 2011 Post only LMWH 1 * Prophylactic or 
therapeutic 
NA 12-24 12-24h maintenance When INR 
therapeutic 
Clark, 2015 Not 
specified 
LMWH, UFH NR Prophylactic or 
therapeutic 
NR NR NR NR NR 
Constans, 2007 Pre/post LMWH Aceno-
coumarol: 3 
Warfarin:  5 
prophylactic  12 <24 1 day after 
procedure 
maintenance On day 3-4 
postoperatively 
Douketis, 2005 Pre/post LMWH 5-6 Prophylactic or 
therapeutic 
 12 24 Evening or day 
after procedure 
NR NR 
Dunn, 2007 Pre/post LMWH 5 therapeutic Morning prior  12-24 Evening of 
procedure or day 
after 
maintenance When INR 
therapeutic 
Eisele, 2012 Pre/post LMWH Mean 6.4 Prophylactic, sub- 
or therapeutic 
Mean 16.2 Mean 12.2 Mean 3.6d NR Overall duration 
mean 7d 
Fernandez, 
2009 
Pre/post, 
post only 
LMWH 4-5 Therapeutic  24 12-48 Evening of 
procedure or day 
after 
NR NR 
Garcia, 2008 Not 
specified 
Almost 
exclusively 
LMWH 
>7 (6.3%) 
5 (87.4%) 
NR NR NR NR NR NR 
Hammerstingl, 
2009 
Pre/post LMWH 5-6 therapeutic Evening prior  NR NR NR When INR 
therapeutic 
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   Preoperative Management Postoperative Management 
Study Peri-
procedural 
Bridging 
Type of 
Bridging 
Anticoagulant 
VKA 
Interruption, 
d 
Dosing of Bridging 
Anticoagulant 
Last Dose of 
LMWH, h 
Restart of 
LMWH, h 
Restart of VKA Initial Dosing 
of VKA 
Stop of Bridging 
Hwang, 2017 Pre/post LMWH 5 therapeutic Morning prior  48-72 after 
major, 12-24 
after minor 
surgery 
With LMWH or day 
after 
loading When INR 
therapeutic on 
2d 
Jaffer, 2005 Pre/post LMWH 5-6 
depending 
on INR 
therapeutic 24 24 Day of procedure 
or day after 
maintenance When INR 
therapeutic on 
2d 
Klamroth, 2010 Pre/post LMWH 7 Half-therapeutic  12 8-12 At provider’s 
discretion (mean 
5d) 
NR When INR 
therapeutic 
Majluf-Cruz, 
2011 
Not 
specified 
LMWH, 
rivaroxaban† 
10 prophylactic NR NR NR NR NR 
Malato, 2010 Pre/post LMWH 5 Subtherapeutic or 
prophylactic 
Evening prior  12 Day after 
procedure 
maintenance When INR 
therapeutic 
McBane, 2010 Pre/post, 
pre only, 
post only 
LMWH 5 therapeutic 24 (only ½ 
dose) 
24-48 Mean 3.9d maintenance When INR 
therapeutic on 
2d 
Pengo, 2009 Pre/post LMWH 5 Subtherapeutic or 
prophylactic 
 12  12 Day after 
procedure 
loading When INR 
therapeutic, 6d 
Sacullo, 2012 Pre/post LMWH 5 Prophylactic or 
subtherapeutic 
Evening prior  12 Day after 
procedure 
maintenance When INR 
therapeutic 
Santamaria, 
2013 
Pre/post LMWH, UFH Aceno-
coumarol: 3 
Warfarin:  5 
prophylactic  12 Evening of 
procedure 
Day after 
procedure 
NR 5-6d after 
procedure 
Sjögren, 2017 Not 
specified 
LMWH NR Prophylactic, sub- 
or therapeutic 
NR NR NR NR NR 
Skeith, 2012 Post only LMWH 5 Prophylactic or 
therapeutic 
NA Morning after 
procedure 
Day of surgery NR At discharge or 
when INR >1.9 
Spyropoulos, 
2004 
Pre/post LMWH, UFH  4 Prophylactic or 
therapeutic 
Morning prior, 
or evening 
prior at ½ dose 
if procedure 
after 10am  
Evening of 
procedure 
Evening of 
procedure 
maintenance When INR 
therapeutic on 
2d 
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   Preoperative Management Postoperative Management 
Study Peri-
procedural 
Bridging 
Type of 
Bridging 
Anticoagulant 
VKA 
Interruption, 
d 
Dosing of Bridging 
Anticoagulant 
Last Dose of 
LMWH, h 
Restart of 
LMWH, h 
Restart of VKA Initial Dosing 
of VKA 
Stop of Bridging 
Spyropoulos, 
2006 
Pre/post, 
pre only, 
post only 
LMWH‡, UFH NR Therapeutic and 
non-therapeutic 
NR NR <24h after 
procedure in 38.3% 
NR Overall duration 
mean 6.8d 
Wilson, 2001 Pre/post LMWH 5 Prophylactic or 
therapeutic 
NR 12 Evening of 
procedure 
maintenance When INR 
therapeutic 
Wiszniewsky, 
2011 
Pre/post LMWH 2 Half-therapeutic 2-12h at ¼ 
therapeutic 
dose 
6-12  d 4 after surgery loading When INR 
therapeutic on 
2d 
Abbreviations: d, day; h, hours; INR, international normalized ratio; LMWH, low molecular weight heparin; NA, not applicable; NR, not reported; 
UFH, unfractionated heparin; VKA, vitamin K antagonist. 
*and administration of 3mg intravenous Vitamin K  
† this treatment arm was not included in our study, as it did not meet the inclusion criteria 
‡ this treatment arm was not included in our analysis, because outcomes were not specifically reported for patients with prior venous 
thromboembolism 
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Supplemental Table 3. Quality of Individual Studies 
Cohort Studies Consecutive 
Enrollment 
Existence of 
Protocol before 
Enrollment 
Intervention / Control Blinded 
Outcome 
Assessment 
Loss to Follow-up 
<5% 
Risk of Bias 
Setting 
Similar 
Time Frame 
Similar 
Ahmed, 2010 yes no yes yes no NR high 
Baijkin, 2009* NA* yes NA NA no NR very high* 
Birnie, 2013* NA* yes NA NA yes yes very high* 
Breen, 2013 PY no NA NA no NR very high 
Burbury, 2011 PN yes NA NA no yes very high 
Clark, 2015 yes no yes yes no NR high 
Constans, 2007 yes yes NA NA no NR very high 
Douketis, 2005 yes no NA NA no NR very high 
Dunn, 2007 no yes NA NA no NR very high 
Eisele, 2012 no no NA NA no no very high 
Fernandez, 2009 † PN PN PY yes PN NR very high  
Garcia, 2008 no yes yes yes no  yes high  
Hammerstingl, 2009 yes yes NA NA no NR very high 
Hwang, 2017 no no NA NA no NR very high 
Jaffer, 2005 yes PN NA NA no NR very high 
Klamroth, 2010 yes PY NA NA no NR very high 
Majluf-Cruz, 2011 † PN PY NA NA no NR very high 
Malato, 2010 yes yes NA NA no yes very high 
McBane, 2010 yes yes yes yes PY yes moderate 
Pengo, 2009 yes yes NA NA no NR very high 
Sacullo, 2012 yes yes NA NA no yes very high 
Santamaria, 2013* NA* yes NA NA no no very high* 
Sjögren, 2017 no no NR NR no NR very high 
Skeith, 2012 no PN yes yes no yes high 
Spyropoulos, 2004 no PN NA NA no  NR very high 
Spyropoulos, 2006 yes PN NA NA yes NR very high 
Wilson, 2001 yes yes NA NA no  NR very high 
Wiszniewsky, 2011 no yes NA NA no NR very high 
 
Abbreviations: NA, not applicable; NR, not reported; PN, probably no; PY, probably yes. Quality of observational studies was assessed using 
criteria adapted from the American College of Chest Physicians working group for the 9th guidelines on antithrombotic therapy and prevention of 
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thrombosis, which included guidance to for quality assessment of cohort studies without internal controls.4 Observational or nonrandomized 
interventional studies were considered to be at high risk of bias and were downgraded to moderate risk if the study accounted for and reported 
all of the reported quality elements. On the other hand, they were upgraded to very high risk if they used a single-arm cohort design without an 
internal comparison group, or there are severe or multiple problems with these elements.5 
*these studies were designed as randomized controlled trials comparing bridging to continued VKA or comparing two different bridging 
strategies. We considered these studies to be prospective cohorts for our systematic review, because none of these trials compared bridging and 
VKA interruption without bridging.   
† conference abstract, no corresponding full text published 
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Supplemental Table 4. Quality of Evidence: Periprocedural Bridging in Patients with Previous VTE 
Quality assessment Summary 
Outcome 
No. of 
studies 
(design) 
Risk of 
Bias* Inconsistency† Indirectness‡ Imprecision§ 
Publication 
Bias || 
No Bridging Bridging 
Quality 
No. of 
procedures 
Pooled 
incidence, % 
(95% CI) 
No. of 
procedures 
Pooled 
incidence, % 
(95% CI) 
Perioperative 
VTE 
27 (cohort 
studies) 
very high consistent direct imprecise substantial 3459 0.5 (0.3-0.8) 3427 0.7 (0.4-1.2) 
very 
low 
Major 
bleeding 
15 (cohort 
studies 
very high inconsistent direct imprecise substantial 2084 0.4 (0.1-1.5) 1702 1.8 (1.2-2.5) 
very 
low 
Any bleeding 
18 (cohort 
studies 
very high inconsistent direct precise substantial 3420 0.4 (0.1-1.7) 3420 3.9 (2.0-7.4) 
very 
low 
Abbreviations: CI, confidence interval; VTE, venous thromboembolism. Quality of evidence was assessed using the GRADE (grading of 
recommendations assessment, development, and evaluation) framework.6 Observational studies were considered low quality of evidence, and 
were downgraded to very low quality depending on risk of bias, inconsistency, indirectness, imprecision, and publication bias. One of four 
possible scores (high, moderate, low, or very low) for the quality of the overall body of evidence was assigned for each outcome. 
*based on following criteria: failure to develop appropriate eligibility criteria, lack of internal control group (single-arm cohorts), flawed 
measurement of exposure and/or outcome, inadequacy of control for confounding, incomplete follow-up.  
† based on differences in effect sizes of studies comparing outcomes in both exposure groups, their overlap in 95% confidence intervals, and 
statistical heterogeneity  
‡ evidence was considered indirect if the population, the intervention, or the outcomes that were measured in the included studies differed 
from those of interest in our systematic review, or if there were no head-to-head comparisons available 
§ based on optimal information size criterion and 95% confidence interval 
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|| The potential for publication bias was determined by searching for unpublished literature and conducting a sensitivity analysis excluding 
conference abstracts. A quantitative assessment of publication bias was not supported by the data (mostly single-arm studies). 
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